US 12,384,784 B2
Polymorphs of Acalabrutinib, a Bruton's tyrosine kinase inhibitor
Geena Malhotra, Mumbai (IN); Venkata Srinivas Pullela, Bangalore (IN); Srinivas Laxminarayan Pathi, Bangalore (IN); Ramanaiah Chennuru, Andhra Pradesh (IN); Ramesh Devarapalli, Andhra Pradesh (IN); and Ashok Mithun, Bangalore (IN)
Assigned to Cipla Limited, Maharashtra (IN)
Appl. No. 17/279,235
Filed by CIPLA LIMITED, Maharashtra (IN)
PCT Filed Sep. 24, 2019, PCT No. PCT/IN2019/050696
§ 371(c)(1), (2) Date Mar. 24, 2021,
PCT Pub. No. WO2020/065667, PCT Pub. Date Apr. 2, 2020.
Claims priority of application No. 201821036102 (IN), filed on Sep. 25, 2018.
Prior Publication US 2022/0002302 A1, Jan. 6, 2022
Int. Cl. C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) [C07B 2200/13 (2013.01)] 6 Claims
OG exemplary drawing
 
1. A crystalline form of acalabrutinib, selected from:
crystalline form-C3 characterized by X-ray powder diffraction (XRPD) pattern peaks at 8.5, 10.0, 11.7, 12.9, 15.3, 17.9, 18.3, 20.1 and 21.6±0.2° 2Θ;
crystalline form-C4 characterized by X-ray powder diffraction (XRPD) pattern peaks at 8.3, 9.9, 12.1, 15.4, 15.9, 16.7, 19.9, 21.5, and 24.4±0.2° 2Θ; and
crystalline form-C5 characterized by X-ray powder diffraction (XRPD) pattern peaks at 7.7, 9.4, 10.8, 13.3, 15.4, 17.3, 22.0, and 23.1±0.2° 2Θ.